Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | WDR5 | P61964 | 2/20 | 0.46 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ACLY | P53396 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | BRD1 | O95696 | 1/20 | 0.41 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.41 |
| ▸ | BRPF3 | Q9ULD4 | 1/20 | 0.41 |
| ▸ | ALPL | P05186 | 1/20 | 0.40 |
| ▸ | EDNRB | P24530 | 2/20 | 0.40 |
| ▸ | EDNRA | P25101 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31050364 | 0.85 | SMN1; SMN2 (0.46) | SMN1; SMN2TSHRGLAGAATRPV4 | |
| SCHEMBL30514814 | 0.85 | SMN1; SMN2 (0.65) | SMN1; SMN2TSHRGLAGAAWDR5 | |
| SCHEMBL1790129 | 0.85 | SMN1; SMN2 (0.65) | SMN1; SMN2TSHRGLAGAAWDR5 | |
| SCHEMBL17315165 | 0.83 | SMN1; SMN2 (0.47) | SMN1; SMN2TSHRGLAGAAWDR5 | |
| SCHEMBL16005133 | 0.83 | PKM (0.53) | SMN1; SMN2TSHRGLAGAAWDR5 | |
| SCHEMBL31556387 | 0.83 | PKM (0.53) | SMN1; SMN2TSHRGLAGAAWDR5 | |
| SCHEMBL4018384 | 0.83 | TRPV4 (0.66) | SMN1; SMN2TSHRGLAGAAWDR5 | |
| SCHEMBL2653076 | 0.79 | ALPL (0.52) | WDR5ALPL | |
| SCHEMBL2719702 | 0.78 | CA12 (0.54) | SMN1; SMN2GAATRPV4ALDH1A1ALPL | |
| SCHEMBL12888826 | 0.78 | MCOLN3 (0.57) | SMN1; SMN2TSHRGAATRPV4HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3668856-B1 | NOVEL TETRAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF TUBERCULOSIS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-06-23 | — | — | EP | disclosed |
| US-20190210970-A1 | PHENYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2019-07-11 | — | — | US | disclosed |
| US-10266495-B2 | Phenyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | FORMA TM2, INC. (US) | 2019-04-23 | — | — | US | disclosed |
| EP-3194375-B1 | PHENYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS INC (US) | 2018-11-21 | — | — | EP | disclosed |
| US-20180327361-A1 | PHENYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2018-11-15 | — | — | US | disclosed |
| US-10005734-B2 | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | FORMA THERAPEUTICS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-10005734-B2 | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | FORMA THERAPEUTICS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| EP-3194375-A1 | PHENYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | Forma Therapeutics, Inc. (US) | 2017-07-26 | — | — | EP | disclosed |
| US-20160083349-A1 | PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2016-03-24 | — | — | US | disclosed |
| WO-2016044782-A1 | PHENYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-03-24 | — | — | WO | disclosed |
| WO-2016044782-A1 | PHENYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-03-24 | — | — | WO | disclosed |
| US-20160083349-A1 | PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2016-03-24 | — | — | US | disclosed |
| US-20160083349-A1 | PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2016-03-24 | — | — | US | disclosed |
| WO-2009001127-A1 | CYANOCYCLOPROPYLCARBOXAMIDES AS CATHEPSIN INHIBITORS | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | WO | disclosed |
| WO-2009001127-A1 | CYANOCYCLOPROPYLCARBOXAMIDES AS CATHEPSIN INHIBITORS | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005734-B2 | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | IDH3A, IDH1, IDH2 | SMN1; SMN2 1626/4885TSHR 2095/4885GLA 2489/4885 |
| US-10266495-B2 | Phenyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | IDH3A, IDH1, IDH3B | SMN1; SMN2 2358/4885TSHR 3264/4885GLA 2938/4885 |
| US-20190210970-A1 | PHENYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | IDH1, IDH2, IDH3A | SMN1; SMN2 3908/4885TSHR 4777/4885GLA 1222/4885 |
| US-20160083349-A1 | PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | IDH3A, IDH1, IDH2 | SMN1; SMN2 1626/4885TSHR 2095/4885GLA 2489/4885 |
| US-20180327361-A1 | PHENYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | IDH3A, IDH1, IDH3B | SMN1; SMN2 2358/4885TSHR 3264/4885GLA 2938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.